This partnership will revolutionize Pharmarack's digital infrastructure with Snowflake's single, integrated platform to facilitate advanced analytic
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
The company expects meaningful revenue contribution from this long-term agreement
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Dr Reddy’s said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
Subscribe To Our Newsletter & Stay Updated
